Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

64 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 18:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableNot yet recruitingINTERVENTIONAL

Postprandial Regulation of Bone Perfusion in Healthy Individuals

ClinicalTrials.gov · NCT07679516 · Registry updated: 2026-07-09

Condition / research focus: Healthy Adult Participants; Bone Physiology; Bone Blood Flow Regulation; Peptide Hormones
Sponsor: University of Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-07-19. Completion: 2028-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

isotonic saline infusion (other)
Infusion of GIP(1-42) (other)
Infusion of GLP-2(1-33) (other)
Infusion of pramlintide (other)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide

ClinicalTrials.gov · NCT06422325 · Registry updated: 2026-06-09

Condition / research focus: Type 1 Diabetes
Sponsor: Oregon Health and Science University
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-12. Completion: 2025-01-28 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

MPC closed-loop system in insulin only mode (device)
MPC closed-loop system in insulin/pramlintide mode (device)

Where the study takes place — 1 listed sites

Oregon Health and Science University
Portland, Oregon, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1Active, not recruitingINTERVENTIONAL

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

ClinicalTrials.gov · NCT03560960 · Registry updated: 2026-05-28

Condition / research focus: Alzheimer Disease; Mild Cognitive Impairment
Sponsor: Boston University
Countries with listed sites: United States
Registry dates and results: Start: 2020-02-04. Completion: 2026-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide challenge test (drug) — also listed as: Symlin

Where the study takes place — 3 listed sites

Indiana University Alzheimer Disease Center
Indianapolis, Indiana, United States
Site recruitment: Not reported
BU Alzheimer Disease Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Memory Center VA Boston Healthcare
Jamaica Plain, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3WithdrawnINTERVENTIONAL

Tailoring Obesity Treatment Trial

ClinicalTrials.gov · NCT06619015 · Registry updated: 2026-04-17

Condition / research focus: Obesity; Appetite Regulation; PreDiabetes
Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark
Countries with listed sites: Denmark
Registry dates and results: Start: 2025-04-01. Completion: 2025-04-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide Acetate 1 MG/ML (drug) — also listed as: Symlin
Semaglutide Pen Injector (drug) — also listed as: Wegovy
Sodium Chloride 0.9% Inj (drug) — also listed as: isotonic saline solution

Where the study takes place — 1 listed sites

University hospital of Southern Denmark
Esbjerg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

ClinicalTrials.gov · NCT07506369 · Registry updated: 2026-04-01

Condition / research focus: Obesity & Overweight
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-04. Completion: 2028-10 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Amylin (Pramlintide) (drug)
Pancreatic Polypeptide (PP) (drug)
Placebo (NaCl 0.9 % solution) (drug)

Where the study takes place — 1 listed sites

Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Hypersensitivity to Amylin in Post-Traumatic Headache

ClinicalTrials.gov · NCT07340775 · Registry updated: 2026-01-14

Condition / research focus: Headache Disorders, Secondary; Brain Diseases; Headache Disorders; Nervous System Diseases; Central Nervous System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Post-Traumatic Headache; Pain; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Amylin; Pramlintide
Sponsor: Danish Headache Center
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-02. Completion: 2028-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Amylin (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Amylin-Induced Migraine Attacks Without Aura

ClinicalTrials.gov · NCT07340788 · Registry updated: 2026-01-14

Condition / research focus: Headache Disorders, Primary; Headache Disorders; Brain Diseases; Nervous System Diseases; Central Nervous System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Migraine Disorders; Headache; Pain; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Amylin; Pramlintide
Sponsor: Danish Headache Center
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-02. Completion: 2028-10-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Amylin (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

ClinicalTrials.gov · NCT06046417 · Registry updated: 2024-04-18

Condition / research focus: type1diabetes; Diabetes Mellitus, Type 1
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2023-11-30. Completion: 2025-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (drug)
Lyumjev (drug)
Automated Insulin Delivery (AID) system (device)

Where the study takes place — 1 listed sites

Research Institute of the McGill University Health Center
Montreal, Quebec, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

ClinicalTrials.gov · NCT04074317 · Registry updated: 2024-03-27

Condition / research focus: Diabetes Mellitus, Type 1; Insulin-dependent Diabetes Mellitus
Sponsor: Xeris Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2019-08-22. Completion: 2020-04-02 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PRAM9 (drug)
Regular Insulin + Pramlintide (drug)
Regular Insulin (drug)

Where the study takes place — 1 listed sites

World Wide Clinical Trials
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Role of Amylin in Bone Metabolism

ClinicalTrials.gov · NCT06186063 · Registry updated: 2024-02-21

Condition / research focus: Bone Diseases, Metabolic; Type 1 Diabetes
Sponsor: Filip Krag Knop
Countries with listed sites: Denmark
Registry dates and results: Start: 2024-02-12. Completion: 2024-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (other)
Placebo (saline) infusion (other)

Where the study takes place — 1 listed sites

Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

ClinicalTrials.gov · NCT05199714 · Registry updated: 2023-10-25

Condition / research focus: Type 1 Diabetes
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2022-02-21. Completion: 2023-03-25 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fiasp (drug)
Artificial Pancreas (device)
Pramlintide (drug)
Aspart (drug)

Where the study takes place — 1 listed sites

Research Institute of the McGill University Health Center
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

ClinicalTrials.gov · NCT01841359 · Registry updated: 2023-06-29

Condition / research focus: Hypoglycemia; Evidence of Previous Gastric Surgery
Sponsor: Joslin Diabetes Center
Countries with listed sites: United States
Registry dates and results: Start: 2010-02-02. Completion: 2022-02-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (drug) — also listed as: Symlin

Where the study takes place — 1 listed sites

Joslin Diabetes Center
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1WithdrawnINTERVENTIONAL

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

ClinicalTrials.gov · NCT04252612 · Registry updated: 2023-06-28

Condition / research focus: Cutaneous Squamous Cell Carcinoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2020-01-30. Completion: 2023-06-26 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (drug) — also listed as: Symlin, SymlinPen

Where the study takes place — 1 listed sites

Moffitt Cancer Center
Tampa, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes

ClinicalTrials.gov · NCT04243629 · Registry updated: 2023-03-15

Condition / research focus: Diabetes Mellitus, Type 1; Type 1 Diabetes; Postprandial Hyperglycemia
Sponsor: McGill University
Countries with listed sites: Canada
Registry dates and results: Start: 2021-11-12. Completion: 2024-04 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Rapid-Acting Insulin (drug)
Placebo (drug)
Pramlintide Acetate (drug)
Artificial Pancreas (device)

Where the study takes place — 1 listed sites

McGill University Health Centre
Montreal, Quebec, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

ClinicalTrials.gov · NCT00691158 · Registry updated: 2022-12-16

Condition / research focus: Obesity
Sponsor: Oregon Health and Science University
Countries with listed sites: United States
Registry dates and results: Start: 2006-01. Completion: 2024-07 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (Amylin) (drug) — also listed as: Amylin
Placebo (Normal Saline) (drug) — also listed as: Placebo
2 Metreleptin (drug) — also listed as: Leptin
Leptin plus Pramlintide (drug) — also listed as: Leptin and Amylin

Where the study takes place — 1 listed sites

Oregon Health & Science University
Portland, Oregon, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

ClinicalTrials.gov · NCT04163874 · Registry updated: 2022-10-10

Condition / research focus: Type 1 Diabetes; Type 1 Diabetes Mellitus; Hyperglycemia, Postprandial
Sponsor: McGill University
Countries with listed sites: Canada
Registry dates and results: Start: 2020-02-14. Completion: 2022-01-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fiasp (drug)
Pramlintide Acetate (drug)
Placebo (drug)
Artificial Pancreas (device)

Where the study takes place — 1 listed sites

3555 University Street
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Glucagon Counterregulation in Type 1 Diabetes

ClinicalTrials.gov · NCT03547427 · Registry updated: 2022-03-28

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: University of Virginia
Countries with listed sites: United States
Registry dates and results: Start: 2018-05-20. Completion: 2019-03-11 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Basal insulin alone (other)
Basal pramlintide and reduced basal insulin (other)
CGM (other)
Acetaminophen test (other)
Insulin-induced hypoglycemia (other)
Exercise-induced hypoglycemia (other)

Where the study takes place — 1 listed sites

University of Virginia Center for Diabetes Technology
Charlottesville, Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

Safety and Efficacy of BC LisPram

ClinicalTrials.gov · NCT04972175 · Registry updated: 2022-02-16

Condition / research focus: Type1 Diabetes Mellitus
Sponsor: Michael Tsoukas
Countries with listed sites: Canada
Registry dates and results: Start: 2021-07-28. Completion: 2022-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

50-Hour Intervention - Rapid Insulin lispro (drug)
50-Hour Intervention - BC LisPram (drug)

Where the study takes place — 1 listed sites

Hygea Medical Clinic
Montreal, Quebec, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

ClinicalTrials.gov · NCT00732147 · Registry updated: 2021-07-22

Condition / research focus: Type 2 Diabetes
Sponsor: University of Maryland, Baltimore
Countries with listed sites: No country reported
Registry dates and results: Start: 2009-04. Completion: 2011-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide acetate (drug) — also listed as: Symlin
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting

ClinicalTrials.gov · NCT03800875 · Registry updated: 2021-06-08

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: McGill University
Countries with listed sites: Canada
Registry dates and results: Start: 2019-02-08. Completion: 2020-09-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

27-hour inpatient intervention (drug)

Where the study takes place — 1 listed sites

McGill University Health Centre
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

64 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 18:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableNot yet recruitingINTERVENTIONAL

Postprandial Regulation of Bone Perfusion in Healthy Individuals

ClinicalTrials.gov · NCT07679516 · Registry updated: 2026-07-09

Condition / research focus: Healthy Adult Participants; Bone Physiology; Bone Blood Flow Regulation; Peptide Hormones
Sponsor: University of Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-07-19. Completion: 2028-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

isotonic saline infusion (other)
Infusion of GIP(1-42) (other)
Infusion of GLP-2(1-33) (other)
Infusion of pramlintide (other)

Where the study takes place — 1 listed sites

Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide

ClinicalTrials.gov · NCT06422325 · Registry updated: 2026-06-09

Condition / research focus: Type 1 Diabetes
Sponsor: Oregon Health and Science University
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-12. Completion: 2025-01-28 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

MPC closed-loop system in insulin only mode (device)
MPC closed-loop system in insulin/pramlintide mode (device)

Where the study takes place — 1 listed sites

Oregon Health and Science University
Portland, Oregon, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1Active, not recruitingINTERVENTIONAL

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

ClinicalTrials.gov · NCT03560960 · Registry updated: 2026-05-28

Condition / research focus: Alzheimer Disease; Mild Cognitive Impairment
Sponsor: Boston University
Countries with listed sites: United States
Registry dates and results: Start: 2020-02-04. Completion: 2026-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide challenge test (drug) — also listed as: Symlin

Where the study takes place — 3 listed sites

Indiana University Alzheimer Disease Center
Indianapolis, Indiana, United States
Site recruitment: Not reported
BU Alzheimer Disease Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Memory Center VA Boston Healthcare
Jamaica Plain, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3WithdrawnINTERVENTIONAL

Tailoring Obesity Treatment Trial

ClinicalTrials.gov · NCT06619015 · Registry updated: 2026-04-17

Condition / research focus: Obesity; Appetite Regulation; PreDiabetes
Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark
Countries with listed sites: Denmark
Registry dates and results: Start: 2025-04-01. Completion: 2025-04-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide Acetate 1 MG/ML (drug) — also listed as: Symlin
Semaglutide Pen Injector (drug) — also listed as: Wegovy
Sodium Chloride 0.9% Inj (drug) — also listed as: isotonic saline solution

Where the study takes place — 1 listed sites

University hospital of Southern Denmark
Esbjerg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

ClinicalTrials.gov · NCT07506369 · Registry updated: 2026-04-01

Condition / research focus: Obesity & Overweight
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-04. Completion: 2028-10 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Amylin (Pramlintide) (drug)
Pancreatic Polypeptide (PP) (drug)
Placebo (NaCl 0.9 % solution) (drug)

Where the study takes place — 1 listed sites

Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Hypersensitivity to Amylin in Post-Traumatic Headache

ClinicalTrials.gov · NCT07340775 · Registry updated: 2026-01-14

Condition / research focus: Headache Disorders, Secondary; Brain Diseases; Headache Disorders; Nervous System Diseases; Central Nervous System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Post-Traumatic Headache; Pain; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Amylin; Pramlintide
Sponsor: Danish Headache Center
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-02. Completion: 2028-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Amylin (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Amylin-Induced Migraine Attacks Without Aura

ClinicalTrials.gov · NCT07340788 · Registry updated: 2026-01-14

Condition / research focus: Headache Disorders, Primary; Headache Disorders; Brain Diseases; Nervous System Diseases; Central Nervous System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Migraine Disorders; Headache; Pain; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Amylin; Pramlintide
Sponsor: Danish Headache Center
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-02. Completion: 2028-10-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Amylin (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

ClinicalTrials.gov · NCT06046417 · Registry updated: 2024-04-18

Condition / research focus: type1diabetes; Diabetes Mellitus, Type 1
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2023-11-30. Completion: 2025-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (drug)
Lyumjev (drug)
Automated Insulin Delivery (AID) system (device)

Where the study takes place — 1 listed sites

Research Institute of the McGill University Health Center
Montreal, Quebec, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

ClinicalTrials.gov · NCT04074317 · Registry updated: 2024-03-27

Condition / research focus: Diabetes Mellitus, Type 1; Insulin-dependent Diabetes Mellitus
Sponsor: Xeris Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2019-08-22. Completion: 2020-04-02 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PRAM9 (drug)
Regular Insulin + Pramlintide (drug)
Regular Insulin (drug)

Where the study takes place — 1 listed sites

World Wide Clinical Trials
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Role of Amylin in Bone Metabolism

ClinicalTrials.gov · NCT06186063 · Registry updated: 2024-02-21

Condition / research focus: Bone Diseases, Metabolic; Type 1 Diabetes
Sponsor: Filip Krag Knop
Countries with listed sites: Denmark
Registry dates and results: Start: 2024-02-12. Completion: 2024-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (other)
Placebo (saline) infusion (other)

Where the study takes place — 1 listed sites

Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

ClinicalTrials.gov · NCT05199714 · Registry updated: 2023-10-25

Condition / research focus: Type 1 Diabetes
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2022-02-21. Completion: 2023-03-25 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fiasp (drug)
Artificial Pancreas (device)
Pramlintide (drug)
Aspart (drug)

Where the study takes place — 1 listed sites

Research Institute of the McGill University Health Center
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

ClinicalTrials.gov · NCT01841359 · Registry updated: 2023-06-29

Condition / research focus: Hypoglycemia; Evidence of Previous Gastric Surgery
Sponsor: Joslin Diabetes Center
Countries with listed sites: United States
Registry dates and results: Start: 2010-02-02. Completion: 2022-02-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (drug) — also listed as: Symlin

Where the study takes place — 1 listed sites

Joslin Diabetes Center
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1WithdrawnINTERVENTIONAL

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

ClinicalTrials.gov · NCT04252612 · Registry updated: 2023-06-28

Condition / research focus: Cutaneous Squamous Cell Carcinoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2020-01-30. Completion: 2023-06-26 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (drug) — also listed as: Symlin, SymlinPen

Where the study takes place — 1 listed sites

Moffitt Cancer Center
Tampa, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes

ClinicalTrials.gov · NCT04243629 · Registry updated: 2023-03-15

Condition / research focus: Diabetes Mellitus, Type 1; Type 1 Diabetes; Postprandial Hyperglycemia
Sponsor: McGill University
Countries with listed sites: Canada
Registry dates and results: Start: 2021-11-12. Completion: 2024-04 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Rapid-Acting Insulin (drug)
Placebo (drug)
Pramlintide Acetate (drug)
Artificial Pancreas (device)

Where the study takes place — 1 listed sites

McGill University Health Centre
Montreal, Quebec, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

ClinicalTrials.gov · NCT00691158 · Registry updated: 2022-12-16

Condition / research focus: Obesity
Sponsor: Oregon Health and Science University
Countries with listed sites: United States
Registry dates and results: Start: 2006-01. Completion: 2024-07 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide (Amylin) (drug) — also listed as: Amylin
Placebo (Normal Saline) (drug) — also listed as: Placebo
2 Metreleptin (drug) — also listed as: Leptin
Leptin plus Pramlintide (drug) — also listed as: Leptin and Amylin

Where the study takes place — 1 listed sites

Oregon Health & Science University
Portland, Oregon, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

ClinicalTrials.gov · NCT04163874 · Registry updated: 2022-10-10

Condition / research focus: Type 1 Diabetes; Type 1 Diabetes Mellitus; Hyperglycemia, Postprandial
Sponsor: McGill University
Countries with listed sites: Canada
Registry dates and results: Start: 2020-02-14. Completion: 2022-01-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fiasp (drug)
Pramlintide Acetate (drug)
Placebo (drug)
Artificial Pancreas (device)

Where the study takes place — 1 listed sites

3555 University Street
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Glucagon Counterregulation in Type 1 Diabetes

ClinicalTrials.gov · NCT03547427 · Registry updated: 2022-03-28

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: University of Virginia
Countries with listed sites: United States
Registry dates and results: Start: 2018-05-20. Completion: 2019-03-11 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Basal insulin alone (other)
Basal pramlintide and reduced basal insulin (other)
CGM (other)
Acetaminophen test (other)
Insulin-induced hypoglycemia (other)
Exercise-induced hypoglycemia (other)

Where the study takes place — 1 listed sites

University of Virginia Center for Diabetes Technology
Charlottesville, Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

Safety and Efficacy of BC LisPram

ClinicalTrials.gov · NCT04972175 · Registry updated: 2022-02-16

Condition / research focus: Type1 Diabetes Mellitus
Sponsor: Michael Tsoukas
Countries with listed sites: Canada
Registry dates and results: Start: 2021-07-28. Completion: 2022-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

50-Hour Intervention - Rapid Insulin lispro (drug)
50-Hour Intervention - BC LisPram (drug)

Where the study takes place — 1 listed sites

Hygea Medical Clinic
Montreal, Quebec, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

ClinicalTrials.gov · NCT00732147 · Registry updated: 2021-07-22

Condition / research focus: Type 2 Diabetes
Sponsor: University of Maryland, Baltimore
Countries with listed sites: No country reported
Registry dates and results: Start: 2009-04. Completion: 2011-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pramlintide acetate (drug) — also listed as: Symlin
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting

ClinicalTrials.gov · NCT03800875 · Registry updated: 2021-06-08

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: McGill University
Countries with listed sites: Canada
Registry dates and results: Start: 2019-02-08. Completion: 2020-09-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

27-hour inpatient intervention (drug)

Where the study takes place — 1 listed sites

McGill University Health Centre
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →